KD 182
Alternative Names: KD 182; KD-022Latest Information Update: 28 Jul 2021
At a glance
- Originator Nanjing KAEDI Biotech
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for phase-I development in Solid-tumours in China (Parenteral)
- 22 Jun 2018 Phase-I clinical trials in Solid tumours in China (Parenteral) (Nanjing KAEDI Biotech pipeline, June 2018)
- 08 Mar 2018 Nanjing KAEDI Biotech has international patent published for KD 022 with Patent Corporation Treaty